**Supplemental Table 2: Complications of decitabine therapy over time by disease phase**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Complication** | **BP** | **AP** | **HR** | **Total** |
| **Bacterial Infection** |  |  |  |  |
| 1 Month | 33.3% | 35.7% | 9.1% | 27.0% |
| 3 Month | 33.3% | 30.0% | 0.0% | 21.7% |
| 6 Month | 0.0% | 66.7% | 25.0% | 33.3% |
| 12 Month | 0.0% | 33.3% | 20.0% | 18.2% |
| 18 Month | 0.0% | 50.0% | 0.0% | 12.5% |
| 24 Month | 0.0% | 50.0% | 0.0% | 16.7% |
| **Viral Infection** |  |  |  |  |
| 1 Month | 0.0% | 0.0% | 9.1% | 2.7% |
| 3 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 6 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 12 Month | 33.3% | 0.0% | 0.0% | 36.4% |
| 18 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 24 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| **Fungal Infection** |  |  |  |  |
| 1 Month | 16.7% | 0.0% | 0.0% | 5.4% |
| 3 Month | 33.3% | 0.0% | 0.0% | 8.7% |
| 6 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 12 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 18 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 24 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| **Arterial Thrombus** |  |  |  |  |
| 1 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 3 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 6 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 12 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 18 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 24 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| **Venous Thrombus** |  |  |  |  |
| 1 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 3 Month | 0.0% | 10.0% | 0.0% | 4.3% |
| 6 Month | 0.0% | 16.7% | 12.5% | 11.8% |
| 12 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 18 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 24 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| **Hemorrhage** |  |  |  |  |
| 1 Month | 0.0% | 0.0% | 9.1% | 2.7% |
| 3 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 6 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 12 Month | 0.0% | 33.3% | 0.0% | 9.1% |
| 18 Month | 0.0% | 0.0% | 0.0% | 0.0% |
| 24 Month | 0.0% | 0.0% | 0.0% | 0.0% |

Bacterial infections are the most common complication, with the highest risk within the first month.